Described herein are X-ray imageable polymers such as polymeric particles comprising bismuth as a radiopacifying agent, methods of making the polymers, and methods of using the polymers. The imageable particles may comprise a covalently bound compound which chelates the bismuth, for example, through a combination of nitrogen and oxygen atoms.

The present invention provides an encapsulated gas or partial vacuum particle contrast media for use in CT imaging. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises, (a) an enteric contrast medium comprising a encapsulated gas or partial vacuum particle suspended in water. Exemplary encapsulated gas or partial vacuum particle has a specific gravity between 0.2 and 1.5. In various embodiments, the encapsulated gas or partial vacuum particle is suspended in aqueous media by an agent compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast material is incorporated into a pharmaceutically acceptable carrier in which the material is suspended homogeneously. In an exemplary embodiment, the encapsulated gas or partial vacuum particle comprises 5% or more of the weight of the contrast material formulation. The invention also provides methods for imaging of the abdomen by dual energy CT or spectral CT contemporaneously with the delivery of the encapsulated gas or partial vacuum particle contrast material into the bowel lumen with or without the deliver of a second complementary contrast material into the blood vessels or other body compartments. The invention also provides methods for the digital separation of CT signal produced by the contrast media of the invention from the CT signal produced by other contrast media or bodily tissues to generate multiple resultant CT images with the contrast medium of the invention subtracted or highlighted.

An example device includes an elongated body defining a lumen, the elongated body comprising a proximal portion and a distal portion; and one or more sensors configured to: stimulate a fluorescence response from one or more fluorescent probes released into a fluid and flowing with the fluid through the lumen; and detect the fluorescence response, wherein the fluorescence response is indicative of a composition of the fluid.

Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Further, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging. The particles may include agents for increasing density for achieving useful buoyancy levels in suspension.

Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Farther, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging. The particles may include agents for increasing density for achieving useful buoyancy levels in suspension.

Spray-dried metal-organic frameworks (MOFs) comprising therapeutic and/or diagnostic metal ions and therapeutic and/or diagnostic organic ligands are described. Both the metal ion and organic ligand can have activity related to the treatment and/or diagnosis of a pulmonary disease or disorder, such as tuberculosis, or another disease related to a pulmonary infection. The MOFs can be adminstered to subjects via inhalation (e.g., as aerosols). Methods of treating and diagnosing pulmonary diseases or disorders are also described.

The present invention provides particulate contrast media for use in CT imaging. In an exemplary embodiment, the invention provides an enteric contrast medium formulation based on particles of low-Z elements selected from microparticles and nanoparticles. In various embodiments, the particles are coated with a material compatible with enteric administration of the formulation to a subject in need of such administration. The invention also provides methods for imaging of body parts simultaneously enhanced with contrast media of the invention and with other contrast media of a different type using CT imaging, including dual energy or spectral CT imaging. The invention also provides methods for the digital separation of CT signal produced by the contrast media of the invention from the CT signal produced by other contrast media or bodily tissues, to generate multiple resultant CT images with individual contrast materials subtracted or highlighted.

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

A developable hyaluronic acid microspherical embolic agent includes a hyaluronic acid and an X-ray opaque contrast material; wherein the hyaluronic acid is a modified hyaluronic acid, wherein a modifying method for preparing the modified hyaluronic acid is cross-linking, grafting, esterification, or recombination, and is preferably cross-linking.

A glass material that includes: from about 0.45 to about 0.86 mole fraction of SiO.sub.2; from about 0.05 to about 0.43 mole fraction of: Y.sub.2O.sub.3, BaO, or a combination of Y.sub.2O.sub.3 and BaO; and optionally Ta.sub.2O.sub.5. The sum of the Y.sub.2O.sub.3, the BaO and the optional Ta.sub.2O.sub.5 is from about 0.10 to about 0.50 mole fraction. The glass includes less than 0.01 mole fraction of Na.sub.2O and less than 0.01 mole fraction of K.sub.2O. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.